Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The Body Protection Compound 157 (BPC-157) receptor refers to the as-yet-unidentified molecular target of the synthetic pentadecapeptide BPC-157, which is derived from a protective protein found in human gastric juice. While a single canonical receptor has not been definitively characterized, BPC-157 is known to exert potent regenerative and cytoprotective effects specifically on damaged tissues and repair-responsive cells, such as fibroblasts and endothelial cells. Its mechanism of action involves the modulation of the nitric oxide (NO) system, the upregulation of vascular endothelial growth factor receptor 2 (VEGFR2), and the activation of the growth hormone receptor signaling pathway. BPC-157 has demonstrated significant therapeutic potential in preclinical models for treating tendon-to-bone injuries, gastric ulcers, and inflammatory bowel disease. Despite its widespread use in experimental research and regenerative medicine circles, the lack of a confirmed molecular target remains a primary challenge for its formal clinical development.
1 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Body Protection Compound 157 receptor.